NICM
ICPT

Neo Ivy Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Neo Ivy Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11
Closed -$1K – 434
2019
Q1 		$1K Buy
+11
New +$1.2K ﹤0.01% 275

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Neo Ivy Capital Management's ICPT Position: Q2 2019 in Review

Neo Ivy Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2019, closing a stake of 11 shares — an estimated $1K sold.

Neo Ivy Capital Management first reported a position in ICPT in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 196 funds tracked by Wall St. Rank hold ICPT as of Q2 2019.

  • Neo Ivy Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Neo Ivy Capital Management sold 11 Intercept Pharmaceuticals, Inc. shares in Q2 2019, an estimated $1K.
  • Neo Ivy Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
  • Neo Ivy Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $1K in Q1 2019.
  • 196 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2019.

Based on Neo Ivy Capital Management's 13F filing for Q2 2019, filed 15 Aug 2019.